Table 1—

Effects on kidney function and arterial blood pressure of increasing doses of candesartan in 23 type 2 diabetic patients with nephropathy

ParameterPlaceboCandesarian dose
8 mg16 mg32 mg
Albuminuria (mg/24-h)*700 (486–1,007)470 (270–778)288 (272–462)332 (176–559)
GFR (ml/min/1.73 m2)84 ± 679 ± 678 ± 677 ± 6
θ Albumin (10−6)*163 (101–262)96 (56–166)85 (48–151)104 (59–210)
θ IgG (10−6)*58 (35–95)36 (22–57)36 (21–63)39 (22–71)
θ IgG4 (10−9)*42 (27–64)30 (18–49)22 (12–39)34 (19–64)
Systolic BP (mmHg)
 24-h147 ± 4138 ± 4138 ± 4134 ± 4
 Day153 ± 4143 ± 4144 ± 4140 ± 4
 Night135 ± 4126 ± 4124 ± 4122 ± 4
Diastolic BP (mmHg)
 24-h78 ± 273 ± 273 ± 271 ± 2
 Day81 ± 276 ± 276 ± 274 ± 2
 Night70 ± 266 ± 267 ± 265 ± 2
  • Data means ± SEM.

  • *

    * Geometric mean (95% CI);

  • P < 0.05 versus placebo;

  • P < 0.01 versus 8 mg.